EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE)

Teresa Marsden iD, Gerhardt Attard, Shonit Punwani, Francesco Giganti, Alex Freeman, Aiman Haider, Anna Wingate, Norman Williams iD, Tom Syer iD, Nora Pashayan, Caroline M Moore, Mark Emberton und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0295994 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2024. Verfasst von Teresa Marsden und 12 weiteren Autor:innen. Beteiligte Einrichtung: UCL Division of Surgical & Interventional Science, University College London, London, United Kingdom. Hauptthemen laut MEDLINE: Disease Progression, Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JP Moulton Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

RECONCILE (ClinicalTrials.gov:NCT04340245) will identify molecular and radiomic markers associated with clinical progression and radiological progression events in a cohort of localised, newly diagnosed Gleason 3 + 4 tumours. Molecular markers will be correlated against standard of care MRI-targeted histology and oncological outcomes.

Methods

RECONCILE is an ethics approved (20/LO/0366) single centre, prospective, longitudinal, observational cohort study of recently diagnosed (within 12 months), organ-confined Gleason 3 + 4 cancers (MCCL ≤10mm) currently under active surveillance. 60 treatment-naïve participants with a concordant MRI lesion (Likert score 4 or 5) and PSA ≤ 15 ng/ml will be recruited. Blood, urine and targeted prostate tissue cores will be subject to next generation sequencing at baseline and one year in all participants. Semen will be collected from a specified sub-population. Baseline and interval MR images will be extracted from standard of care prostate MRI ahead of radiomic analysis. Data extracted from radiological and biological samples will be used to derive the association of molecular change and radiological progression, the primary outcome of the study. To compensate for spatial intratumoral heterogeneity and inherent sampling bias, a molecular index will be derived for each participant using the molecular profile of tumour tissue at both baseline (MolBL) and one year (MolFU). We will extract a ΔMolBL:MolFU score for each participant. Molecular progression will be defined as a MolBL:MolFU score >95% CI of the combined ΔMolBL scores. Radiological progression is defined as a PRECISE score of 4 or 5. The study is powered to detect an association with a statistical power of 80%.

Results

Recruitment began in July 2020 (n = 62). To date, 37 participants have donated tissue for analysis.

Conclusion

We have designed and implemented a prospective, longitudinal study to evaluate the underlying molecular landscape of intermediate risk, MR-visible prostate tumours. Recruitment is ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ProgressionMagnetic Resonance ImagingProstatic NeoplasmsAgedHumansMaleMiddle AgedBiomarkers, TumorLongitudinal StudiesNeoplasm GradingProspective StudiesProstateProstate-Specific AntigenRisk AssessmentObservational Studies as Topic

Substanzen

Biomarkers, TumorProstate-Specific Antigen

Autor:innen und Institutionen

  • UCL Division of Surgical & Interventional Science, University College London, London, United Kingdom.
  • Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Cancer Institute, University College London, London, United Kingdom.
  • Centre for Medical Imaging, University College London, London, United Kingdom.
  • Department of Radiology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Department of Pathology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

ORCID-Profile: Teresa Marsden, Norman Williams, Tom Syer

Förderung

  • JP Moulton Charitable Foundation

Zitieren

APA

Marsden, T., Attard, G., Punwani, S., Giganti, F., Freeman, A., Haider, A., Wingate, A., Williams, N., Syer, T., Pashayan, N., Moore, C. M., Emberton, M., & Orczyk, C. (2024). The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE). PLOS ONE. https://doi.org/10.1371/journal.pone.0295994

Vancouver

Marsden T, Attard G, Punwani S, Giganti F, Freeman A, Haider A, et al. The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE). PLOS ONE. 2024. doi:10.1371/journal.pone.0295994

BibTeX
@article{Marsden2024,
  author = {Marsden, Teresa and Attard, Gerhardt and Punwani, Shonit and Giganti, Francesco and Freeman, Alex and Haider, Aiman and Wingate, Anna and Williams, Norman and Syer, Tom and Pashayan, Nora and Moore, Caroline M and Emberton, Mark and Orczyk, Clement},
  title = {The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE)},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0295994}
}
Kostenlos starten →